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ABSTRACT
Adipose tissue forms when basement membrane extract (MatrigelTM) and fibroblast growth factor-2
(FGF-2) are added to our mouse tissue engineering chamber model. A mouse tumor extract, Matrigel is
unsuitable for human clinical application, and finding an alternative to Matrigel is essential. In this study
we generated adipose tissue in the chamber model without using Matrigel by controlled release of FGF-2 in
a type I collagen matrix. FGF-2 was impregnated into biodegradable gelatin microspheres for its slow
release. The chambers were filled with these microspheres suspended in 60lL collagen gel. Injection of
collagen containing free FGF-2 or collagen containing gelatin microspheres with buffer alone served as
controls. When chambers were harvested 6 weeks after implantation, the volume and weight of the tissue
obtained were higher in the group that received collagen and FGF-2 impregnated microspheres than in
controls. Histologic analysis of tissue constructs showed the formation of de novo adipose tissue accom-
panied by angiogenesis. In contrast, control groups did not show extensive adipose tissue formation. In
conclusion, this study has shown that de novo formation of adipose tissue can be achieved through con-
trolled release of FGF-2 in collagen type I in the absence of Matrigel.
INTRODUCTION
AUTOLOGOUS FAT TRANSPLANTATION is a traditional ap-proach in reconstructive surgery for repair or augmen-
tation of soft tissue defects.1 This technique involves the
transplantation of autologous fat grafts to depressed regions in
the breast or facial areas. However, this method is associated
with certain drawbacks, including donor site morbidity, pro-
gressive resorption of implanted grafts, and some operative
risk.1–4 If the induction of new, vascularized adipose tissue
can be achieved by using tissue-engineering approaches, it
would be a significant breakthrough in reconstructive surgery.
One promising approach is the extended targeting of growth
factors to the site where the tissue is to be regenerated. This
can be achieved by supplying the growth factors to the site
using a controlled-release carrier system.5 One of the growth
factors related to tissue regeneration is fibroblast growth
factor-2 (FGF-2), a potent mitogen and chemoattractant for a
wide array of cells.6 Recent in vitro studies have shown that
FGF-2 enhances adipogenesis of mesenchymal stem cells in
2-dimensional short-term and 3-dimensional long-term cell
culture.7,8 FGF-2 has also been reported to be effective in
inducing angiogenesis and regeneration of bone, cartilage,
and nerve.9–11
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Recent research on tissue regeneration using controlled
release of growth factors from biodegradable hydrogels
shows that it is essential to have efficient combination of the
growth factors with the carrier to induce in vivo tissue re-
generation.5 In general, a growth factor molecule possesses
positively charged sites on its surface under physiologic
conditions.12 Thus, a hydrogel prepared from a polymer with
negative charges can electrostatically interact with posi-
tively charged growth factors to allow physical immobili-
zation. Numerous studies have shown that the negatively
charged, acidic gelatin forms a polyion complex with posi-
tively charged FGF-2 due to electrostatic interaction.13–16
This prevents the denaturation and enzymatic degradation of
FGF-2 in vivo. The FGF-2 is released from gelatin hydrogels
as a result of matrix degradation in vivo. 13–16
It has been demonstrated that adipogenesis in mouse sub-
cutis can be achieved by an injection of MatrigelTM (BD
Biosciences, San Jose, CA) combined with FGF-2.17 It
has also been shown that the controlled release of FGF-2
from gelatin hydrogels significantly enhanced angiogenesis
in vivo,13–19 which is essential for the generation and main-
tenance of adipose tissue. Compared to the implantation of
Matrigel and free FGF-2, the level of adipogenesis was sig-
nificantly higher subcutaneously when Matrigel was used in
conjunction with a FGF-2 release system, such as gelatin
microspheres.20,21 At our institution, a novel technique was
recently developed that enables the formation of de novo
vascularized adipose tissue in vivo in a murine chamber
model.22 The model involves placing a split silicone chamber
(50mL) filled with Matrigel and containing a small fat graft
(approximately 3 mg) around a vascular pedicle comprising
the proximal epigastric blood vessels in the mouse groin. We
have found that access to preexisting fat either through an
opening in the chamber or in the form of an autograft is
essential for effective neoadipogenesis in the chambers.23 The
technique produces angiogenesis and adipogenesis leading
to a vascularized fat flap based on the vascular pedicle.
This ultimately allows microsurgical transfer of the result-
ing adipose tissue to any defect in the body. However,
because Matrigel is extracted from a mouse sarcoma, the at-
tendant immunologic considerations limit its use for tissue
engineering applications in other species due to immu-
nological considerations; it cannot be used for human appli-
cations at all.
The objective of this study was to produce vascularized
adipose tissue in vivo without using Matrigel. By using the
model mentioned previously, we investigated whether col-
lagen has potential to function as a biological scaffold for
adipose tissue formation when used in combination with
gelatin microspheres for controlled release of FGF-2. Var-
ious synthetic and natural polymers have been used as
scaffold in adipose tissue engineering, for example Ma-
trigel17,20,21 and poly(D,L-lactide-co-glycolide).24 Collagen
is one of the most important biomaterials, and it has wide
applications as a carrier for delivery of drugs, proteins, and
genes.25 Collagen has several advantages over other natural
polymers, including biodegradability, weak antigenicity,
and excellent biocompatibility.25 Collagen has also been
used in tissue engineering applications for the development
of heart valves, blood vessels, and ligaments.26 In the con-
text of adipogenesis, it has been reported that different types
of collagen have the ability to promote differentiation of
preadipocytes to mature adipocytes.27–30 Also, adipose tis-
sue engineering by use of freeze-dried collagen sponge
with human preadipocytes has been reported in vitro and
in vivo.19,31,32 However, to our knowledge this is the first
in vivo report on soft tissue engineering using a collagen
hydrogel as a scaffold material. We examined the effect of
collagen hydrogel and gelatin microspheres impregnated
with FGF-2 in chambers on adipose tissue formation. The
chamber specimens were harvested and evaluated histo-
logically for adipose tissue formation and angiogenesis
6 weeks after implantation.
MATERIALS AND METHODS
Materials
Human recombinant FGF-2 was purchased from Aus-
tralian Lab Services (Homebush, Australia), and bovine
dermal collagen (Vitrogen, 3 mg/mL) was purchased from
Cohesion Technologies (Palo Alto, CA). Glutaraldehyde
was purchased from Sigma-Aldrich (Castle Hill, Australia).
The olive oil was purchased from a local food store; gelatin
and other chemicals were purchased from APS Chemicals
Ltd (Seven Hills, Australia) and used without further pur-
ification. Milli Q water (Simplicity System, Millipore
Purification Pak, Millipore, Billerica, MA) containing 1
colony-forming unit of microorganisms per mL or less was
used throughout the experiment.
Preparation of gelatin microspheres
Gelatin microspheres were prepared through glutar-
aldehyde crosslinking of a gelatin aqueous solution in an
emulsion state.33 Immediately after mixing 10 mL of glu-
taraldehyde aqueous solution (25 wt %) with 4 mL of 10 wt %
gelatin aqueous solution preheated at 408C, the mixed so-
lution was added dropwise to 150 mL of olive oil under
stirring at 500 rpm and 408C in a standard 250-mL glass
beaker to obtain a water-in-oil emulsion. After stirring the
reaction mixture for 15 min at 408C, the temperature was
dropped to 258C and stirring was continued for 24 h to allow
the gelatin to chemically crosslink. Acetone (40 mL) was
added to the reaction mixture, and stirring was continued for
another hour. The resulting microspheres were allowed to
settle at the bottom of the centrifuge tubes and were washed
5 times with acetone by centrifugation (48C, 3000 rpm, 5 min
[3K30, Sigma Laboratory Centrifuges]). The washed mi-
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crospheres were placed in 100 mL of 0.1 M glycine aqueous
solution containing Tween 80 (0.1 wt %); stirring continued
at 378C and 1000 rpm for 1 h to block the residual aldehyde
groups of any unreacted glutaraldehyde. The crosslinked
gelatin microspheres were then washed with Milli-Q water
and collected by centrifugation (48C, 3000 rpm, 5 min). The
microspheres were disinfected by storing them in 70%
ethanol.34 Finally, the microspheres were placed under va-
cuum for 24 h to remove the ethanol before incorporating the
FGF-2. FGF-2 was incorporated into microspheres by
dropping the aqueous solution of FGF-2 on vacuum-dried
microspheres as described below.
Morphologic analysis of gelatin microspheres
Gelatin microspheres were coated with gold using a
sputter coater and were examined with a scanning electron
microscope (SEM) (Philips Model XL30, Amsterdam, the
Netherlands) using an accelerating voltage of 12 kV. For
size distribution studies, particles were stained with food
color and examined in a Beckman Coulter apparatus (LS-
130, Langley Ford Instruments, Amherst, MA). Cryo-SEM
(CT 1500, Oxford Instruments, Oxfordshire, United King-
dom) analysis was used to study the distribution and
integration of the gelatin micropsheres in collagen gel. The
neutralized collagen solution (200 mL) carrying the micro-
spheres was placed onto an SEM planchet using a 21-gauge
needle. It was then plunged into liquid propane and there-
after into liquid nitrogen. The sample was fractured at
1858C using a precooled blade and was sublimed at808C
for 1 h before imaging. The image was taken at a working
distance of 24 mm using 2 kV.
Preparation of suspension of gelatin
microspheres with FGF-2 in collagen
The original FGF-2 solution was diluted with Milli-Q
water to a concentration of 1 mg/mL. A 50 mL aliquot of this
solution was dropped onto 5 mg of vacuum-dried gelatin
particles, which were left at room temperature for overnight
impregnation of FGF-2 into microspheres. In vitro release of
FGF-2 was not studied because it has been well documented
that FGF-2 complexed with acidic gelatin is not released
under in vitro conditions in the absence of enzymes.15
However, acidic gelatin hydrogels have been shown to re-
lease biologically active FGF-2 in vivo,15 and the time
profile of FGF-2 retention was in accordance with the in vivo
degradation of acidic gelatin hydrogels.18
Collagen in solution was neutralized by sodium bicarbo-
nate buffer and 10 phosphate-buffered saline (PBS).
Neutralized collagen is liquid at 48C but gels at physiologic
temperature of 378C. Gelatin microspheres with absorbed
FGF-2 solution were homogeneously suspended into the
neutralized collagen solution at 48C using a sterile 1 mL
syringe (Becton Dickinson, Singapore) and transferred in the
same syringe. The same procedure was followed to achieve a
homogeneous suspension of PBS-loaded gelatin micro-
spheres in collagen.
In vivo experiments
Animal experiments were approved by the Animal Ethics
Committee of St. Vincent’s Hospital, Melbourne, Australia.
Male C57Bl6 mice (20–26 g body weight; ARC, Perth,
Australia) were used in all experiments. Surgery was per-
formed in sterile conditions under general anesthesia induced
by an intraperitoneal injection of chloral hydrate (0.4 mg/g
body weight).
Tissue engineering chambers made of silicone laboratory
tubing (Dow-Corning Corp., Midland, MI) were inserted
into both groins of each mouse as described elsewhere.22
The superficial epigastric vessels were exposed via a trans-
verse groin incision and dissected free of their investing
fascia for a distance of approximately 1 cm from their origin
at the femoral vessels to their entry into the groin fat pad.
The cylindrical tissue engineering chamber was then placed
around the vessels and anchored to underlying muscle with
a 10-0 nylon microsuture. The proximal aperture and long-
itudinal seam of the chambers were sealed with melted bone
wax (Ethicon, Somerville, NJ), with care taken not to apply
wax directly to the tissue and a gap left for the pedicle to pass
through; the chambers were filled with the extracellular
matrix and growth factor combination, as detailed below.
Experimental groups
The following groups were adopted and assessed at 6
weeks: I) control chambers filled with collagen and free
FGF-2 without gelatin microspheres (control, n¼ 5),
II) control chambers filled with collagen and gelatin mi-
crospheres with PBS (control, n¼ 4), and III) chambers
filled with collagen and gelatin microspheres impregnated
with FGF-2 (n¼ 5).
Within each group, each animal received bilateral cham-
bers filled with the same treatments, and 1 of each chamber
pair was augmented with a 3-mg autologous fat graft. The fat
graft was removed from the same animal’s epididymal fat pad
at the time of chamber insertion, weighed, and then immersed
within the extracellular matrix (collagen) filling the chamber.
The distal aperture of each chamber was then sealed with
bone wax and the construct carefully returned to the dissected
space within the groin. The wound was closed with metal clips.
All operations were performed by the same surgeon. The
animals were housed in social groups and fed normal chow
and water ad libitum. At harvest, the constructs were deliv-
ered via the transverse groin wound and examined for vessel
pedicle patency. Two constructs had an absent or infracted
pedicle, with necrotic contents. In these chambers, we saw
evidence of microsphere aggregation, which appears to have
compromised the appropriate release of FGF-2. It could be
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that excessively high local concentrations are produced at the
time that is critical for vascular survival and neovasculariza-
tion of the construct. These failed chambers were discarded
from the study.
Harvest and histology
Six weeks after implantation, all animals were sacrificed
and the contents of each patent chamber were analyzed.
The volumes of the tissue specimens were determined by
a volume displacement technique in normal saline at room
temperature. The tissue was fully submerged in the saline
using an entomologic pin, and the weight of the displaced
fluid was recorded.35 The specimens were fixed in 4% par-
aformaldehyde, dehydrated with a graded ethanol series, and
embedded in paraffin as described elsewhere.22 Sections
5 mm thick were stained with hematoxylin-eosin for mor-
phologic analysis and Masson’s trichrome for collagen.
Immunohistochemical analysis was conducted to assess the
angiogenesis by using purified rat anti-mouse CD31 (platelet
endothelial cell adhesion molecule-1) monoclonal antibody
(BD Biosciences).
Statistical analysis
The volume displacement data were analyzed using
2-way analysis of variance (SPSS software, version 12.0,
SPSS Inc., Chicago, IL) with the treatment group as one
variable and presence of an autograft the second. Post hoc
analysis was done using Tukey’s honestly significant dif-
ference test. Differences were considered significant when
the p value was less than .05.
RESULTS
Morphologic analysis of crosslinked
gelatin microspheres
The SEM observations revealed that the gelatin particles
were spherical in shape with smooth surface characteristics
(Fig1A). The particles (70% by volume) were in the range of
20–160 mm in diameter in a swollen state according to the
Coulter apparatus, which was acceptable for our experi-
ments. The literature suggested that micropsheres with dia-
meters in the range of 20–100 mm can be effectively used for
subcutaneous and intramuscular administration.36 Accord-
ing to the cryo-SEM images, some clumping was present
between the beads but a reasonable distribution of the beads
throughout the porous open structure of fibrillar collagen
matrix was achieved (Fig.1B, C). The clumping is noted to
be a result of the crosslinking procedure (i.e., it is not a result
of adding the beads to the collagen gel). We also noted that
the beads integrated with the collagen gel, which is not
surprising as gelatin is denatured collagen. This allows strong
binding of the beads with the carrier matrix, which is ex-
FIG. 1. Scanning electron micrographs of the gelatin microspheres. (A) Representative glutaraldehyde crosslinked gelatin micro-
sphere showing smooth surface and spherical nature (bar ¼ 10 mm). Also depicted are cryo-scanning electron micrograph images of
gelatin microspheres in collagen at lower magnification (B) (bar ¼ 100 mm) and higher magnification (C) (bar ¼ 10 mm), which
illustrate the disperse embedding of the gelatin microspheres into the collagen scaffold.
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pected to improve mechanical properties of the composite
(although these properties were not measured).
Weights and volume displacements
The weight of tissue obtained (Table 1) was highest in the
group that received FGF-2 in a controlled manner from
gelatin micropsheres, whereas the lowest weights were no-
ted in the group with no FGF-2 added. The trends in the
volume displacement data paralleled the weight values
(Fig. 2). Control groups were volumetrically small com-
pared to the group that received gelatin microspheres loaded
with FGF-2; however, there was no significant difference
between the control groups. The slightly higher volume
obtained in the free FGF-2 group compared with the no FGF-
2 group may reflect the availability and activity of ‘‘free’’
FGF-2; however, the sustained release of FGF-2 from mi-
crospheres gave a much stronger result.
Formation of adipose tissue 6 weeks after
implantation of collagen gel and gelatin
microspheres incorporating FGF-2
Figure 3 shows histologic sections of the chamber speci-
mens from all the groups studied following harvest at 6
weeks after implantation. Few scattered adipocytes were
present in the group that received free FGF-2, with very little
formation of new fat and notable residual collagen (Fig. 3A,
B, and H). Significant shrinkage occurred as a result of the
progressive absorption of collagen in the group that received
no FGF-2, and there was no evidence of new fat formation in
this group (Fig. 3C, D). In representative images from this
group, Fig. 3C shows a section in which collagen had almost
completely disappeared, leaving the original fat autograft. In
the group receiving gelatin microspheres with incorporated
FGF-2, both small and matured adipocytes were observed in
the absence or presence of the added fat autograft (Fig. 3E,
F). Also, there was a marked penetration of fibroblastic-
appearing cells or vessels into the residual collagen matrix.
There were signs of active vascularization with formation of
new blood vessels in the collagen matrix (Fig. 3I). The
collagen was replaced by new fat cells, and the amount of
remaining residual collagen surrounding the new tissue was
commensurately lower (Fig. 3G). The amount of adipose
tissue formation was significantly higher in this group than
in the control groups (p< .001). Some inflammatory cells
were present in all groups.
DISCUSSION
Matrigel combined with FGF-2 leads to de novo adipo-
genesis when injected subcutaneously17 or into a perivas-
TABLE 1. BREAKDOWN OF AVERAGE WEIGHTS OF CHAMBER TISSUES IN MILLIGRAMS
IN EACH EXPERIMENTAL CONDITION
Group Autograft No. of Chambers Mean Weight (mg)*
I. Collagen and free FGF-2
(no gelatin microspheres)
þ 5 4.08 (2.80–5.00)
 5 3.25 (1.90–4.70)
II. Collagen and buffer-loaded
gelatin microspheres (no FGF-2)
þ 4 3.75 (3.20–4.70)
 4 2.20 (1.20–3.00)
III. Collagen and FGF-2–loaded
gelatin microspheres
þ 4 8.00 (5.00–9.30)
 4 5.15 (4.30–5.80)
FGF-2 ¼ fibroblast growth factor-2.
*Values in parentheses represent the range.
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FIG. 2. Boxplot of volume displacements for the different
groups and autograft treatments. In group I, collagen and free
fibroblast growth factor-2 (FGF-2) were added without graft ()
and with the fat graft (þ). Note the relatively small amount of
resultant fat and the minor effect of the added fat graft. In group II,
collagen was added with empty gelatin microspheres (no FGF-2)
without () and with (þ) the graft. The complete lack of FGF-2 in
this system resulted in very low adipose tissue yields, but some
adipose tissue formed when the graft was added (group IIþ). In
group III, collagen and FGF-2–loaded gelatin microspheres were
added without () and with (þ) the fat graft, respectively. Here
the sustained release of FGF-2 triggered significant new adipose
tissue, especially when the fat graft was added (p< .001).
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cular chamber22 in mice. The heparin sulfate proteo-
glycan (Perlecan) in Matrigel is known to bind FGF-2 (a
heparin-binding growth factor) and may effect a slow release
of FGF-2.37 In an attempt to confirm this important role of
FGF-2 and to promote adipogenesis without the use of
Matrigel (which ultimately has limited application utility in
tissue engineering), we used gelatin microspheres to provide
prolonged exposure to FGF-2 in vivo and explored the ca-
pacity of collagen as a supportive matrix material. We
used injectable type I collagen (fibrillar collagen), which
provided a 3-dimensional scaffold in our mouse chamber
model.
The present study indicated that adipose tissue can be
generated when collagen is used in conjunction with the
controlled release of FGF-2. Sufficient angiogenesis is a
prerequisite for de novo adipogenesis, and earlier studies
have shown that significant angiogenesis can be indu-
ced through the controlled release of FGF-2 from gelatin
A B C
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FIG. 3. Representative histologic sections of chamber constructs 6 weeks after implantation: sections A–F and I were stained with
hematoxylin-eosin, and sections G and H were stained with Masson’s trichrome. (A) Section containing loose granulation tissue and a
patent pedicle with little adipose tissue present in chamber containing collagen with free fibroblast growth factor-2 and added autograft
(group Iþ). (B) Connective tissue with no adipose tissue present taken from a chamber containing collagen and free FGF-2 without
autograft (group I). (C) Overall view of the chamber containing collagen and gelatin microspheres with phosphate-buffered saline
with autograft added (group IIþ) showing autograft and connective tissue with some adipose tissue at low power (original magnifi-
cation,1.25). (D) Tissue section from chamber containing collagen and gelatin microspheres with phosphate-buffered saline without
autograft showing no adipose tissue present. (E) New adipose tissue growing in chambers with collagen and gelatin microspheres
incorporating FGF-2 with autograft added (group IIIþ). (F) New adipose tissue and connective tissue in chambers containing collagen
and gelatin microspheres incorporating FGF-2 without autograft (group III). (G) Adipose tissue from chambers containing collagen
and gelatin microspheres impregnated with FGF-2, showing good vasculature and a thin capsule. (H) Connective tissue from a chamber
containing collagen and free FGF-2, showing some loose connective tissue and residual collagen scaffold with minimal adipose tissue
formation. (I) Section labeled with CD31 (brown staining) showing good vascular development in the neoadipose tissue, taken from a
chamber containing collagen and gelatin microspheres loaded with FGF-2 with autograft added. All scale bars ¼ 100mm. Color images
for A–F available online at www.liebertpub.com/ten.
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hydrogels.13–16 It is possible that the controlled release
of FGF-2 induced angiogenesis in the collagen matrix,
resulting in migration, proliferation, and maturation of pre-
adipocyte precursors to ultimately facilitate adipogenesis in
the chamber. Also, from the histologic findings in the control
group that received free FGF-2 and collagen, it can be
concluded that the absence of a sustained FGF-2–release
system resulted in insufficient angiogenesis, ultimately
leading to very little or no fat formation. However, some
effect of the free FGF-2 was apparent since there was no sign
of new fat growing in the complete absence of FGF-2,
whereas some fat formation was noted in the free FGF-2
group. The reduced adipogenesis in group I can be explained
by early disappearance of free FGF-2 because collagen is not
an ideal carrier of FGF-2.38 Free FGF-2 probably resulted in
poor angiogenic effect, causing less formation of fat. The
higher amount of fat in chambers receiving the autograft
confirmed an important inductive role for preexisting fat in
adipogenesis, as previously indicated.23
Although we had hypothesized that components of Ma-
trigel other than FGF-2 would be essential for adipogenesis
in our chamber, the results show that sustained release of
FGF-2 alone is sufficient given an appropriate scaffold. In
line with our findings, FGF-2 is essential for the Matrigel-
induced adipogenesis;17 in addition, since heparin sulfate
proteoglycan has been shown not only to bind FGF-2 but
also to be essential for appropriate FGF-2 activity,37 heparin
sulfate proteoglycan or the laminin component of Matrigel
may be essential for appropriate FGF-2 release in these
chambers. This is also consistent with the finding of Kimura
et al., who showed that the FGF-2–loaded gelatin micro-
spheres used in conjunction with a subcutaneous collagen
sponge and exogenous human preadipocytes were adipo-
genic and resulted in new human adipose tissue.19 However,
our study substantially differed in the use of self-contained
chamber, hydrated collagen rather than a sponge, and ab-
sence (in our case) of human preadipocytes. We reasoned
that the previous investigators’ use of exogenous preadi-
pocytes may have obviated some Matrigel requirement;
however, our current data suggest otherwise, that appro-
priate sustained or slow release of the FGF-2 in a collagen
scaffold is sufficient to induce adipogenesis and we do not
need other constituents of Matrigel, such as laminin and
other growth factors. This was supported by the observa-
tion of increased adipose tissue when FGF-2 was added
with microspheres to the collagen matrix, and this will
greatly simplify the development of appropriate 3-dimen-
sional constructs required for adipose tissue engineering.
Our hypothesis is that heparin sulfate proteoglycan, perhaps
bound to the laminin that is abundant in Matrigel, is the
essential component that facilitates FGF-2 availability and
release.
The optimal matrix for adipose tissue regeneration is not
yet known. Collagen scaffolds have also been shown to
function as suitable carriers for preadipocytes, which
are most commonly used as a cell source for cell-based
strategies for adipose tissue engineering.19,31,32,39 Three-
dimensional collagen scaffolds can facilitate the vascular-
ization process,40 which is essential fordenovo adipogenesis.
Collagen is a widely used biomaterial in regeneration of
tissues, and its porous structure facilitates cellular ingrowth
and synthesis of new matrix.41– 43 One of the major ad-
vantages of using collagen is that it can be formulated as an
injectable hydrogel, which is ideally suited for our appli-
cation of delivering FGF-2–loaded gelatin microspheres in a
chamber model. In our study, collagen provided good in-
filtration of cells and showed little inflammatory effect, but it
tends to be absorbed once the new tissue is generated. This
resulted in lower volumes of tissue being obtained compared
to the more resilient Matrigel matrix.22 Contraction of the
collagen was apparent, resulting in dumbbell-shaped tissues,
although no substantial capsule was noted. We hypothesized
that a collagen formulation that is more resistant to de-
gradation should lead to a larger adipose outcome; however,
glutaraldehyde crosslinking would compromise the bioac-
tivity of the FGF-2 inside the gelatin micropsheres that we
dispersed into the collagen solution before gelation.
In addition to providing the appropriate release kinetics for
FGF-2, Matrigel also has some physical properties that make
it an ideal medium for tissue engineering generally, including
adipose tissue. Being composed of the major structural pro-
tein components of many tissues, laminin I and collagen IV,
it has highly tunable mechanical properties that are strongly
dependent on both temperature and concentration (e.g., the
elastic modulus [at 378C] can be varied from 0.01 to 0.1 kPa
by increasing concentration from 2 to 10 mg/mL), allowing it
to be injected to the site (with or without cells) and thereafter
fill the desired space with some resistance to deformation.
Additionally, Matrigel is relatively resistant to foreign body
response and proteolytic removal; remnants of Matrigel can
be clearly seen after 6 weeks in vivo. This makes it an ideal
scaffold; however, the source of Matrigel from a transplan-
table tumor in mice and its likely immunogenicity limit its
utility. Our finding in a controlled environment indicate
that prolonged bioavailability of FGF-2 is the major role of
Matrigel. The results hold promise for the replacement of
Matrigel with more practical alternatives without the added
complexity of providing additional biological components
from Matrigel, which could have potentially been required.
The current study was performed at 6 weeks to provide a
comparative basis with Matrigel-induced tissue engineering
in the same chambers.22,23 Since we have revealed the major
role of FGF-2, we can direct our studies to providing a scaf-
fold. Future studies of scaffolds will address other key issues
for successful adipose tissue engineering, such as construct
size or long-term permanence, since engineered adipose tis-
sue has been shown to resorb once the scaffold resorbs.44 Our
observations suggest that while some residual collagen could
be seen at 6 weeks, it suffers from rapid clearance, and we are
working to optimize the mechanical properties of the collagen
in order to better support the structure of the newly generated
tissue in both time and space.
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